At Chicago's annual gathering of the American Society of Clinical Oncology, cancer researchers presented a pancreatic cancer treatment that accomplished what seemed unattainable just years ago: doubling survival times for patients facing one of the deadliest diagnoses in oncology. Among more than 7,000 studies presented at the summit, the work on daraxonrasib, developed by American start-up Revolution Medicines, stood out as a watershed moment—the first major breakthrough against advanced pancreatic cancer in decades.
The results speak plainly. Half of the patients studied survived for more than 13 months, compared to roughly six and a half months for those receiving standard chemotherapy. "I think this represents an unprecedented paradigm shift in how we're treating advanced pancreatic cancer," said oncologist Monty Pal, capturing the significance of a shift that could reshape treatment for one of medicine's most intractable challenges. What makes daraxonrasib particularly promising is that it targets a protein implicated in several types of cancer—a protein that, until recently, had resisted every therapeutic attempt.
Beyond pancreatic cancer, the summit unveiled intriguing early-stage evidence that familiar weight-loss medications might play a role in slowing cancer progression. GLP-1 agonists like Ozempic and Wegovy, originally developed for diabetes, showed a 38 to 50 percent reduction in disease progression across four cancer types—lung, breast, colorectal, and liver—when compared to conventional diabetes treatments. The finding is particularly relevant given that millions of American patients with obesity and diabetes, already at elevated risk for certain cancers, use these drugs regularly. Study author Mark Orland cautioned that confirmation through randomized clinical trials is still needed, calling the current results "just the start," but the possibility that a widely prescribed medication might also help prevent cancer from advancing represents a genuine opening.
The meeting also highlighted a quieter but equally important shift: doing less harm. A major clinical trial demonstrated that some breast cancer patients don't need surgical removal of armpit lymph nodes—a procedure called axillary lymph node dissection that carries significant long-term side effects. For patients whose cancer has spread to just one or two lymph nodes, the surgery proved unnecessary. "We are probably way over performing actually lymph node dissections, and causing long term side effects in our patients when it's unnecessary," said Julie Gralow, ASCO vice president. This reframing—recognizing that sparing patients from unnecessary intervention is itself a form of progress—reflects a maturing understanding of how to personalize cancer care.
For men with prostate cancer, an international trial unveiled an exceptional combination therapy. Researchers tested two drugs together in patients carrying genetic mutations that typically lead to more aggressive disease: enzalutamide, which blocks the hormonal signals powering tumors, and talazoparib, which disrupts the cancer cells' ability to repair their DNA. For patients with the BRCA2 mutation, this combination reduced the risk of tumor progression or death by 65 percent. "The results are exceptional and a major step forward," said Karim Fizazi, the French-Moroccan professor who coordinated the study. Prostate cancer remains the most common cancer among men and the second-leading cause of cancer deaths, making such advances particularly consequential.
What emerged from Chicago was not a single silver-bullet cure, but rather a portrait of oncology in flux—more precise, more personalized, and increasingly willing to question assumptions about what patients actually need.